Influenza A virus neuraminidase N3 (N3) (N3)

Influenza A virus neuraminidase N3 is a critical surface glycoprotein and enzyme found in specific subtypes of the Influenza A virus, most notably in avian-origin strains like H7N3 [UniProt: P06755]. It functions as a glycosyl hydrolase that cleaves terminal sialic acid residues from glycoconjugates on the host cell surface and the viral envelope [PubMed: 11706160]. This enzymatic activity is indispensable for the viral life cycle, as it enables the release of newly formed virions from the infected cell and prevents their entrapment in respiratory mucus [PubMed: 11117921]. By facilitating the spread of the virus to uninfected cells, N3 plays a central role in the pathogenesis of influenza infections. Therapeutically, N3 is targeted by neuraminidase inhibitors such as oseltamivir and zanamivir, which occupy the enzyme's active site to prevent substrate cleavage [PubMed: 10601631]. These interventions are vital for managing outbreaks, although the potential for mutations leading to drug resistance remains a significant clinical concern [PubMed: 22126314].

Other names

Neuraminidase subtype N3SialidaseNAExo-alpha-sialidaseN3 neuraminidase

Neuraminidase inhibitors competitively bind to the highly conserved active site of the N3 enzyme, preventing the hydrolysis of terminal sialic acid residues. This inhibition traps progeny virions at the host cell surface and within the respiratory mucus, thereby preventing the spread of the virus to uninfected cells [PubMed: 10601631, PubMed: 11117921].